• Next Post
  • Previous Post

test

/ Uncategorized

Share the Post

About the Author

Related Posts

Biomarker Analysis From AMPECT Correlating Response to nab-Sirolimus in PEComa With TSC1 and TSC2 Inactivating Alterations
Aadi Bioscience Initiates Rolling Submission of NDA to FDA for nab-sirolimus (ABI-009, FYARRO™) for the Treatment of Advanced Malignant PEComa
Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer
Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement
Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa)
Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit
Response to Treatment With nab-Sirolimus Among Patients With Malignant PEComa of Uterine Origin: A Subanalysis From AMPECT 
Aadi Bioscience Recieves FDA’ Orphan Product Development Grant for Treatment of Advanced PEComa

Comments

Comments are closed.

  • Next Post
  • Previous Post